Eyeworld

by Title Heading Name title Contact Name: email 46 | EYEWORLD | JULY 2021 ASCRS NEWS A SCRS Subspecialty Day will take place on Friday, July 23, and will include the ASCRS Refractive Day, ASCRS Cornea Day, and ASCRS Glaucoma Day programs. The chairs of these programs spoke to EyeWorld about what attend- ees can expect. ASCRS Subspecialty Day preview 1 CAUTION: Federal law restricts this device to sale by or on the order of a physician. INDICATIONS FOR USE: The Hydrus Microstent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: The Hydrus Microstent is contraindicated under the following circumstances or conditions: (1) In eyes with angle closure glaucoma; and (2) In eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber (AC) angle. WARNINGS: Clear media for adequate visualization is required. Conditions such as corneal haze, corneal opacity or other conditions may inhibit gonioscopic view of the intended implant location. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, peripheral anterior synechiae (PAS), angle closure, rubeosis and any other angle abnormalities that could lead to improper placement of the stent and pose a hazard. PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the Hydrus Microstent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, eyes with significant prior trauma, eyes with abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, eyes with preexisting pseudophakia, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open angle glaucoma, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes that have undergone argon laser trabeculoplasty (ALT ), eyes with unmedicated IOP < 22 mm Hg or > 34 mm Hg, eyes with medicated IOP > 31 mm Hg, eyes requiring > 4 ocular hypotensive medications prior to surgery, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment and when implantation is without concomitant cataract surgery with IOL implantation. The safety and effectiveness of use of more than a single Hydrus Microstent has not been established. ADVERSE EVENTS: Common post-operative adverse events reported in the randomized pivotal trial included partial or complete device obstruction (7.3%); worsening in visual field MD by > 2.5 dB compared with preoperative (4.3% vs 5.3% for cataract surgery alone); device malposition (1.4%); and BCVA loss of ≥ 2 ETDRS lines ≥ 3 months (1.4% vs 1.6% for cataract surgery alone). For additional adverse event information, please refer to the Instructions for Use. MRI INFORMATION: The Hydrus Microstent is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions. Please see the Instructions for Use for complete product information. References: 1. Ahmed, I.K. (2021, Mar. 4-7). 5 Year Follow Up from the HORIZON Trial. American Glaucoma Society Virtual Annual Meeting. *Data on file—includes trabeculectomy and tube shunt. ©2021 Ivantis, Inc. Ivantis and Hydrus are registered trademarks of Ivantis, Inc. All rights reserved. IM-0098-1 Rev A Refractive Day ASCRS Refractive Day is chaired by Eric Donnenfeld, MD, Cathleen McCabe, MD, and Vance Thompson, MD, with more than 50 ophthalmologists invited as expert faculty. The program chairs described it as "an exciting oppor- tunity for clinicians to evaluate the efficacy of conventional and new advanced technologies to improve the preopera- tive evaluation and postoperative results of patients under- going cornea and lens-based refractive surgery." "We will have sessions covering the advantages and disadvantages of new refractive IOL materials, design, and cornea technologies, such as trifocals, extended depth of focus IOLs, topographic and wavefront ablations, and SMILE," Drs. Donnenfeld, McCabe, and Thompson said. "We are excited to have the Steinert Refractive Lecture given by the first person to perform excimer laser photoab- lation, Marguerite McDonald, MD, who will speak about presbyopia-correcting topical medications," they said. "Refractive Day will be the one stop for everything attend- ees need to know about refractive cornea and cataract surgery with the perfect mix of didactic and case-based presentations." ANNUAL MEETING PREVIEW

• Blank Page
• Blank Page (1)